Agnidipta Sarkar, Group CISO, Biocon moves on
Cybersecurity leader Agnidipta Sarkar has left Biocon, where he was the Group CISO.
He was at India’s leading and largest innovation-led biopharmaceutical company for about two and a half years. Founded by Kiran Mazumdar-Shaw, Biocon is an Indian biopharmaceutical company headquartered in Bangalore. The company manufactures generic active pharmaceutical ingredients.
As the Group CISO at Biocon, he enabled and supported the Group’s business and digital transformation initiatives by continuously transforming digital resilience and cybersecurity capabilities to protect the information entrusted by customers. He also ensured compliance with applicable regulations to help the Group maintain and improve its market position.
The digital resilience practitioner and cyber crisis specialist was part of a large number of digital transformation initiatives and used his capabilities, competencies, and experience to ensure a steady balance between enabling the economic architecture of Biocon’s digital business (revenues, margin, user experience and satisfaction) and the cyber threat that the businesses, customers, and team members faced. He used that opportunity to build vision, strategies, and structures by leveraging and improving upon available expertise, tools, frameworks, and operating procedures to address complex cybersecurity and cyber resilience challenges.
In his own words, the zero trust ambassador and standards evangelist says: “The challenges required me to not only have a sound knowledge of how businesses use information but also to collaborate and innovate controls in an evolving digital ecosystem.”
With more than 3 decades of experience in the cybersecurity vertical, Sarkar has worked with some of the top global companies such as Biocon, CMS IT services, DXC Technologies, HPE, HP Inc, and more.
Although Sarkar hasn’t divulged the exact details about his upcoming stint, he has indicated that he will be working for an OEM in a CISO advisory role.
Â
Source: https://bit.ly/3RGn7kf